GWPH News
Archived Headlines
- 6 US IPOs planned for the week of Apr 29 04/29/13
- US IPO Recap: Fairway jumps 45% in six-deal week 04/22/13
- Cannibinoid therapeutics company GW Pharmaceuticals sets terms for $38 million IPO 04/18/13
- US IPO Weekly Recap: Seven deals price, six new filers 03/25/13
- UK-based cannabinoid therapeutics developer GW Pharmaceuticals files for US IPO 03/19/13
Will it trade high? Cannabis biotech Zynerba Pharmaceuticals sets terms for $42 million IPO
Zynerba Pharmaceuticals, a preclinical biotech developing cannabinoid-based therapies for osteoarthritis and epilepsy, announced terms for its IPO on Thursday. The Devon, PA-based company plans to raise $42 million by offering 3.0 million shares at a price...read more
Uncovering the cannabis cure: Zynerba Pharmaceuticals files for a $58 million IPO
Zynerba Pharmaceuticals, a preclinical biotech developing cannabinoid-based therapies for osteoarthritis and epilepsy, filed on Wednesday with the SEC to raise up to $58 million in an initial public offering. The last cannabinoid-based health care IPO...read more
US IPO Recap: Activity remains robust with five pricings, five setting terms and four new filers
Following last week's market break, US IPO activity resumed where it left off last week with five pricings, including ING U.S. (VOYA), which raised $1.3 billion. However, overall performance was subpar, with four of five of the deals achieving a total return...read more
GW Pharmaceuticals prices IPO at $8.90
GW Pharmaceuticals, which develops and commercializes cannabinoid-based therapeutics, raised $31 million by offering 3.5 million shares at $8.90. The offer price represents an 11% discount to the closing price of GW Pharma's AIM listing in London on March 18,...read more